Josep M. Llibre

Genotypic Determination of HIV Tropism – Clinical and Methodological Recommendations to Guide the Therapeutic Use of CCR5 Antagonists

Once-Daily Single-Tablet Regimens: A Long and Winding Road to Excellence in Antiretroviral Treatment

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

First-Line Boosted Protease Inhibitor-Based Regimens in Treatment-Naive HIV-1-Infected Patients – Making a Good Thing Better

Genetic Barrier to Resistance for Dolutegravir

Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review

HIV-1 Genotypic Drug Resistance Interpretation Rules – 2009 Spanish Guidelines

From TMC114 to Darunavir: Five Years of Data on Efficacy

Update on Clinical and Methodological Recommendations for Genotypic Determination of HIV tropism to Guide the Usage of CCR5 Antagonists